Press release
Prurigo Nodularis Treatment And Management Market Intelligence Study for Comprehensive Insights
One such platform was founded in 2014, The Prurigo Nodularis League (PNL) which serves as a mutual platform for patients, doctors and academics to come together in discourse of this disease. Prurigo nodularis has a huge scope of research as there is yet no classification of various pruriginous forms. Despite its prevalence and severity, prurigo nodularis is still an unknown skin disease. The goal of PNL is to raise the global awareness related to the etiology and pathogenesis of prurigo nodularis and the ongoing research.
Request Report TOC @ https://www.futuremarketinsights.com/toc/rep-gb-3339
The potential of prurigo nodularis treatment and management market has increased the number of clinical trials undertaken by various market players. For instance, Trevi Therapeutics had started a pivotal trial of of Nalbuphine ER. The company plans to carry out the prurigo nodularis study on 60 prurigo nodularis patients from Europe and US. Recently the company reported positive Phase II trial result for the treatment of severe or moderate prurigo nodularis. The startup could gather USD 26 million for its Nalbuphine ER for the treatment of prurigo nodularis.
Treatment of prurigo nodularis is difficult due to the intensity of itching. Initially, the patient is prescribed with potent steroid creams along with antihistamines such as Zonalon, Pramoxine, Atarax and Perjactin for additional relief. In cases of severe prurigo nodularis, cyrotherapy and steroids may be used. Resistant cases are diagnosed using biopsy and blood tests of the sores.
Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-3339
Geographically, prurigo nodularis treatment and management market is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East and Africa. North America and Europe region is projected to maintain its lions share over the forecast period. The amount of research funding and awareness initiatives are higher in this region. On behalf of Trevi Therapeutics, Inc. a U.S. based company MediciGlobal launched a new website to provide access to clinical trial related information of prurigo nodularis. Europe is the second largest region in terms of revenue share as it also has number of clinical trials ongoing. Velocity Pharmaceutical Development, LLC ("VPD") and Menlo Therapeutics Inc, received permission from the Germany's BfArM to initiate Phase II studies of VPD-737 (serlopitant) in patients with prurigo nodularis. Asia Pacific is expected to be the fastest growing region for the prurigo nodularis treatment and management market.
Key Players
Some of the key players in prurigo nodularis treatment and management market include Velocity Pharmaceutical Development, LLC; Menlo Therapeutics Inc, Trevi Therapeutics, Inc.; GlaxoSmithKline plc, Mylan N.V., UCB, PharmaDerm and Aspen Holdings to name a few.
Pre Book Full Report – https://www.futuremarketinsights.com/checkout/3339
ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website :www.futuremarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prurigo Nodularis Treatment And Management Market Intelligence Study for Comprehensive Insights here
News-ID: 865836 • Views: …
More Releases from Future Market Insights
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
More Releases for Prurigo
Prurigo Nodularis Market Growth, Applications, Innovations and Business Outlook …
Introduction
Prurigo nodularis (PN) is a rare, chronic inflammatory skin disease characterized by intensely itchy nodules that severely impair quality of life. The exact cause remains unclear, but PN is linked to immune dysregulation, chronic pruritus pathways, and systemic diseases such as atopic dermatitis, diabetes, and liver disorders. For decades, management relied on corticosteroids, antihistamines, and immunosuppressants, with limited efficacy and safety concerns in long-term use.
The landscape has changed dramatically with…
Prurigo Nodularis Treatment Market Opportunities & Challenges, Novel Therapies T …
The Global Prurigo Nodularis Treatment Market reached USD 964.3 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1.1 billion by 2031. The Global Prurigo Nodularis Treatment Market is exhibiting at a CAGR of 3.7% during the forecast period 2024-2031.
Prurigo Nodularis Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to…
Prurigo Nodularis Pipeline: Emerging Therapies Set to Reshape the Prurigo Nodula …
The treatment landscape of Prurigo Nodularis (PN), a chronic, intensely pruritic skin disorder, is undergoing a dynamic transformation, fueled by a growing pipeline of novel therapeutics from leading pharma and biotech companies. Notable players such as Menlo Therapeutics, Galderma R&D, and Kiniksa Pharmaceuticals are driving innovation with therapies targeting underlying immune dysregulation, including IL-31 and JAK/STAT pathways, central to PN pathogenesis. These emerging drugs aim to address the high unmet…
Prurigo Nodularis Treatment Market Current Status and Future Prospects till 2031
Prurigo Nodularis (PN) is a chronic dermatologic condition marked by intense itching and the development of nodules on the skin. The Prurigo Nodularis Treatment Market focuses on therapeutic interventions to alleviate symptoms and provide relief to patients suffering from this condition. Treatments include topical corticosteroids, immunosuppressants, and biologic therapies. The current market value of Prurigo Nodularis treatment is driven by the increasing awareness of PN and advancements in treatment options.…
Prurigo Nodularis Treatment Market Size, Share | Forecast 2032
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Prurigo Nodularis Treatment Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.
Market Overview for Prurigo Nodularis Treatment Market
Prurigo Nodularis Treatment Market OverviewPrurigo nodularis (PN) is a chronic skin condition characterized by intensely itchy nodules or papules that can significantly impair quality of…
Prurigo nodularis Market: F: Information, Figures and Analytical Insights 2021-2 …
The Prurigo nodularis Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. We analyzed the…
